SOURCE: Equity News Circuit

Equity News Circuit

April 23, 2013 08:45 ET

Free Research Reports on ABIO, DCTH, MUX and XIDE Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - Apr 23, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Arca Biopharma Inc. (NASDAQ: ABIO) shares soared 47.21 percent on volume of 2.35 million shares traded Monday to close at $2.90. The company announced that it will collaborate with Medtronic on Arca's proposed atrial fibrillation clinical trial of Gencaro. Shares of the company are up approximately 27 percent year-to-date.

Find out more about Arca Biopharma including full access to the free equity report at: www.BedfordReport.com/ABIO

Delcath Systems, Inc. (NASDAQ: DCTH) shares gained 9.61 percent on volume of 2.70 million shares traded Monday to close at $1.54 a share. The company earlier this month announced that it has received a notification from the FDA extending the initial Prescription Drug User Fee Act goal date for the review of the New Drug Application for Melblez.

Find out more about Delcath Systems including full access to the free equity report at: www.BedfordReport.com/DCTH

McEwen Mining Inc. (NYSE: MUX) shares declined 5.67 percent on volume of nearly 6.0 million shares traded Monday to close at $1.83. The company recently reported that exploratory drilling results at the El Gallo 1 mine show potential to both increase the size of the gold resource and extend the mine life.

Find out more about McEwen Mining including full access to the free equity report at: www.BedfordReport.com/MUX

Exide Technologies (NASDAQ: XIDE) shares spiked 10.69 percent in late trade Monday to close at $1.45 a share. The company earlier this month announced that it has retained the financial advisory firm of Lazard to advise "the company on financing alternatives to maximize the value of the company for all stakeholders."

Find out more about Exide Technologies including full access to the free equity report at: www.BedfordReport.com/XIDE

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information